Price Alert

Silence Therapeutics (SLN)

NASDAQ: SLN · Real-Time Price · USD

5.48

-0.15 (-2.66%)

At close: Aug 15, 2025, 3:59 PM

5.49

0.09%

After-hours: Aug 15, 2025, 04:10 PM EDT

-2.66% (1D)

Bid	5.43
Market Cap	258.84M
Revenue (ttm)	26.21M
Net Income (ttm)	-56.93M
EPS (ttm)	-1.68
PE Ratio (ttm)	-3.26
Forward PE	-12.38
Analyst	Buy

Ask	6.28
Volume	87,154
Avg. Volume (20D)	109,572
Open	5.61
Previous Close	5.63
Day's Range	5.45 - 5.91
52-Week Range	1.97 - 20.48
Beta	1.39

About SLN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SLN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SLN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Silence Therapeutics has released their quartely earnings on Aug 7, 2025:

Revenue of $224K misses estimates by $5.21M, with -70.37% YoY decline.

EPS of -0.57 misses estimates by -0.34, with -35.71% YoY decline.

Next Earnings Release

Silence Therapeutics is scheduled to release its earnings on Nov 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

-15.45%

Silence Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

News

1 week ago · businesswire.com

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...

2 months ago · businesswire.com

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) th...

2 months ago · zacks.com

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

2 months ago · zacks.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

The mean of analysts' price targets for Silence Therapeutics (SLN) points to a 590.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a...